BR0115689A - Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata - Google Patents

Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata

Info

Publication number
BR0115689A
BR0115689A BR0115689-6A BR0115689A BR0115689A BR 0115689 A BR0115689 A BR 0115689A BR 0115689 A BR0115689 A BR 0115689A BR 0115689 A BR0115689 A BR 0115689A
Authority
BR
Brazil
Prior art keywords
prostate cancer
treatment
nucleic acid
diagnosis
polypeptide
Prior art date
Application number
BR0115689-6A
Other languages
English (en)
Inventor
Kimberly A Gillis
Yixian Zhang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0115689A publication Critical patent/BR0115689A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"ANáLISE DE EXPRESSãO DE INIBIDOR DE DIFERENCIAçãO DE áCIDOS NUCLéICOS E POLIPEPTìDEOS úTEIS NA DIAGNOSE E TRATAMENTO DE CâNCER DA PRóSTATA". A invenção refere-se a composições, kits e métodos para detectar, caracterizar, prevenir, e tratar câncer da próstata. Os marcadores de ID são fornecidos, em que alterações nos níveis de expressão de um ou mais dos marcadores de ID estão correlacionadas com a presença de câncer da próstata.
BR0115689-6A 2000-11-28 2001-11-28 Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata BR0115689A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25337400P 2000-11-28 2000-11-28
PCT/US2001/044495 WO2002044417A2 (en) 2000-11-28 2001-11-28 Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Publications (1)

Publication Number Publication Date
BR0115689A true BR0115689A (pt) 2004-02-10

Family

ID=22959998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115689-6A BR0115689A (pt) 2000-11-28 2001-11-28 Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata

Country Status (14)

Country Link
US (1) US20020182614A1 (pt)
EP (1) EP1356107A2 (pt)
JP (1) JP2004526424A (pt)
AU (1) AU2002239363A1 (pt)
BR (1) BR0115689A (pt)
CA (1) CA2429721A1 (pt)
HU (1) HUP0303890A3 (pt)
IL (1) IL155953A0 (pt)
MX (1) MXPA03004577A (pt)
NO (1) NO20032393L (pt)
NZ (1) NZ526706A (pt)
PL (1) PL365794A1 (pt)
WO (1) WO2002044417A2 (pt)
ZA (1) ZA200304997B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422320A1 (en) * 2000-09-14 2002-03-21 The Regents Of The University Of California Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
CA2505416A1 (en) * 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
US20060194211A1 (en) * 2003-04-29 2006-08-31 Burczynski Michael E Methods for prognosis and treatment of solid tumors
WO2005026370A2 (en) * 2003-09-05 2005-03-24 Sanofi Pasteur Limted. Multi-antigen vectors for melanoma
WO2007109881A1 (en) * 2006-03-24 2007-10-04 Phenomenome Discoveries Inc. Biomarkers useful for diagnosing prostate cancer, and methods thereof
KR20220126661A (ko) * 2021-03-08 2022-09-16 (주)아큐레시스바이오 췌장암의 진단용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005283A1 (en) * 1995-08-01 1997-02-13 Sloan-Kettering Institute For Cancer Research Id AS A DIAGNOSTIC MARKER IN TUMOR CELLS
AU2024799A (en) * 1998-01-09 1999-07-26 President And Fellows Of Harvard College Immortalization of primary human keratinocytes by the helix-loop-helix protein, id-1
EP1047793B1 (en) * 1998-01-21 2006-11-15 Dianon Systems, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
CA2422320A1 (en) * 2000-09-14 2002-03-21 The Regents Of The University Of California Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma

Also Published As

Publication number Publication date
HUP0303890A3 (en) 2006-03-28
WO2002044417A2 (en) 2002-06-06
IL155953A0 (en) 2003-12-23
NO20032393D0 (no) 2003-05-27
EP1356107A2 (en) 2003-10-29
CA2429721A1 (en) 2002-06-06
WO2002044417A9 (en) 2003-11-20
NZ526706A (en) 2005-03-24
HUP0303890A2 (hu) 2004-03-01
ZA200304997B (en) 2004-09-27
AU2002239363A1 (en) 2002-06-11
WO2002044417A3 (en) 2003-07-24
NO20032393L (no) 2003-07-03
US20020182614A1 (en) 2002-12-05
PL365794A1 (en) 2005-01-10
JP2004526424A (ja) 2004-09-02
MXPA03004577A (es) 2003-09-04

Similar Documents

Publication Publication Date Title
BR0115715A (pt) Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
BR0016569A (pt) Processo de isolamento de rna de espécimes de tecido embutidos - parafina fixados - formalina
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
BR0210579A (pt) Anticorpos, cadeias pesadas e leves, composição farmacêutica e métodos de detecção do nìvel de opgl em amostra biológia e de tratamento
BR9911291A (pt) Diagnóstico diferencial de neurodegeneração
DE69940969D1 (de) Detektion von neoplasien durch speichelanalyse
BRPI0413471A (pt) métodos para detectar um ou mais complexos de proteìnas e para detectar um complexo em uma amostra biológica
WO2001036977A8 (en) Identification of disease markers involving mass-based-separation
BRPI0407397A (pt) Evento de algodão mon 88913 e composições e métodos para sua detecção
BRPI9912227A (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
BRPI0208597B8 (pt) meio de detecção de staphylococcus aureus e/ou estafilococos com coagulose positiva e método de identificação de bactéria (s) da espécie staphylococcus aureus em uma amostra
WO2005010215A3 (en) Methods for identifying tolerance modulatory compounds and uses therefor
BR0003072A (pt) Fechadura de cilindro dotada de meios de orientação magneticamente operados
DE60239059D1 (de) Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums beingen einer antiöstrogen-therapie resistent sind
DE60027045D1 (de) Oligonukleotide und diese enthaltende komplexe zur detektion der anwesenheit oder abwesenheit einer zielnukleinsäure in einer probe
BR0115689A (pt) Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
ATE350662T1 (de) Markerproteine für prostatakrebs
BR9607854A (pt) Processos para a medição da taxa de degradação de uma proteína do corpo e para obtenção de informação referente à degradação de proteína em um paciente utilização de um isômero sintético de um peptídeo e de um anticorpo anticorpo capa de células análogo de peptídeo sintético e kit de análise para utilização em um processo de análise
HUP0100668A2 (hu) Virulenciával kapcsolatos nukleinsavszekvenciák és alkalmazásuk
BR0108659A (pt) Métodos para tratamento ou prevenção ou profilaxia de câncer de mama, para detecção, diagnóstico e/ou avaliação ou prognóstico quanto ao câncer de mama, para monitoração e/ou estimativa de tratamento do câncer de mama, para identificação da presença ou ausência de células de câncer de mama metastáticas em um amostra biológica e para avaliação ou identificação de compostos, usos de uma ou mais bcmps, de uma composição, de um anticorpo, de ácido nucleico e de um agente que interaja com ou module a atividade de uma ou mais bcmps, vacina, composição, kit e anticorpo
DE60029413D1 (de) Enzymatische messung von mycophenolsäure
BR0012676A (pt) Métodos para tratamento de tumores resistentes a terapia
DE69739317D1 (de) Früher nachweis einer lysosomalen speicher-krankheit
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
BR0115728A (pt) Análise da expressão de ácidos nucléicos kiaa e polipeptìdeos úteis no diagnóstico e tratamento de cáncer de próstata

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.